Clinical trial
High Dose Camptothecin-11 (CPT-11) in Recurrent Unresectable Malignant Glioma
NCT00283556 · Kentuckiana Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00283556 |
|---|---|
| Title | High Dose Camptothecin-11 (CPT-11) in Recurrent Unresectable Malignant Glioma |
| Official title | Phase I/II Study of High Dose Irinotecan (Camptosar, CPT-11) in Patients With Recurrent Unresectable Malignant Glioma on Steroids/Anti-epileptics |
| Lead sponsor | Kentuckiana Cancer Institute, Other |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Malignant Glioma |
| Intervention type | Drug |
| Interventions | Irinotecan (Camptosar, CPT-11) |
| Enrollment | 30 |
| Start date | Aug 1, 2001 |
| Primary completion | Dec 1, 2008 |
| Completion | Dec 1, 2008 |
| First posted | Jan 30, 2006 |
| Last update posted | Jan 20, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: